Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Évaluation d'EXL01, un nouveau produit biothérapeutique vivant pour prévenir la récidive de l'infection à Clostridioides difficile chez les patients à haut risque (LIVEDIFF)

19 octobre 2026 mis à jour par: Hospices Civils de Lyon

Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea in Europe, with over 120,000 cases and almost 3,700 deaths per year. This infection is characterized by a high risk of recurrence after cure, ranging from almost 20% after a first episode to over 60% after 2 recurrences, or in the case of specific risk factors.

Currently, first-line treatment of CDI is based on oral antibiotics such as fidaxomicin or vancomycin. These antibiotic treatments, which are effective in 89% and 86% of first-episode cases respectively, do not correct the microbiological imbalance underlying the onset of CDI and may, on the contrary, encourage recurrence by contributing to the maintenance of a deleterious change in the microbiota (dysbiosis) through the elimination of bacteria other than C. difficile, due to their spectrum of activity. In a number of patients, this ecological imbalance can no longer be restored after antibiotic treatment, leading to multiple recurrences of CDI.

In this context, fecal microbiota transplantation (FMT) has been validated for over 10 years for the prevention of recurrence in multi-recurrent CDI. The principle of FMT is based on the use of a pharmaceutical preparation made from the stool of a healthy donor, administered within the digestive tract of a patient for therapeutic purposes.

Currently, in the case of multiple recurrences, it is the recommended first-line treatment (from 2 recurrences) and the most effective, with a clinical efficacy preventing recurrence of CDI in 69% to 89% of cases at 8 weeks post-treatment, with a good safety profile.

Among the microbial factors promoting CDI, the loss of the bacterial species Faecalibacterium prausnitzii constitutes a specific therapeutic target. F. prausnitzii is a commensal bacterium of the human gut, making up nearly 5% of the fecal microbiota, and has been shown to be associated with an individual's state of health. A drop in its relative abundance is associated with an increased risk of numerous diseases, such as Crohn's disease and colorectal cancer. In CDI, F prausnitzii is greatly diminished. Moreover, low abundance of F. prausnitzii is predictive of C. difficile recurrence. Its abundance in stools is increased after FMT and is also predictive of response to treatment. From a pathophysiological point of view, one of the preventive effects of F. prausnitzii on recurrence would be mediated by its ability to hydrolyze the bile acids involved in the germination of C. difficile spores.

The aim of this Phase I/II trial is to assess the efficacy and safety of oral administration of EXL01, a single isolated unmodified strain of F. prausnitzii, in preventing CDI recurrence in high-risk patients at W8. The study will be conducted in 2 parts. The phase I (Part A) is planned to include 6 patients. The phase II (Part B) will include 50 patients in two arms (25 patients respectively in the placebo and EXL01 arm).

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

56

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Annecy, France
        • Pas encore de recrutement
        • CH Annecy Genevois Service de Maladies infectieuses
        • Contact:
        • Chercheur principal:
          • Emilie PIET, MD
      • Clermont-Ferrand, France, 63003
        • Recrutement
        • Service d'hépato-gastroentérologie - CHU Estaing
        • Contact:
        • Chercheur principal:
          • Julien SCANZI, MD
      • Grenoble, France
        • Recrutement
        • CHU Grenoble Service Maladies infectieuses et tropicales
        • Contact:
        • Chercheur principal:
          • Salomé GALLET, MD
      • Lille, France
        • Recrutement
        • CHU Lille Unité des Maladies Infectieuses et tropicales
        • Contact:
        • Chercheur principal:
          • Sarah STABLER, MD
      • Lyon, France, 69004
        • Recrutement
        • Service d'Hépato-gastroentérologie Hôpital de la Croix Rousse
        • Contact:
        • Chercheur principal:
          • Nicolas BENECH, MD
        • Contact:
      • Marseille, France
        • Recrutement
        • APHM La Timone Service de Maladies infectieuses
        • Contact:
        • Chercheur principal:
          • Nadim CASSIR, MD
      • Paris, France, 75012
        • Recrutement
        • Service d'hépato-gastroentérologie - Hôpital Saint Antoine (APHP)
        • Contact:
        • Chercheur principal:
          • Paul MCLELLAN, MD
      • Saint-Etienne, France, 42100
        • Recrutement
        • Service d'infectiologie - Hôpital Nord / CHU Saint Etienne
        • Contact:
        • Chercheur principal:
          • Elisabeth BOTHELO-NEVERS, Pr
      • Toulouse, France, 31059
        • Recrutement
        • Service de médecine interne - Pôle des maladies de l'appareil digestif - CHU de Toulouse
        • Chercheur principal:
          • Laurent ALRIC, Pr
        • Contact:
      • Valence, France, 26000
        • Recrutement
        • Service de Maladies Infectieuses - CH de Valence
        • Contact:
        • Chercheur principal:
          • Amélie DUREAULT, MD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adult patient ≥18 years of age

  • ≥3rd episode of proven C. difficile infection (≥3 liquid stools per day and detection of toxigenic C. difficile in stool by PCR or enzyme-linked immunosorbent assay or immunochromatography or toxigenic culture) within 6 months with an interval ≤ 12 weeks since the end of treatment of the previous episode of resolved CDI or 2nd episode of proven C. difficile infection (≥3 liquid stools per day and detection of toxigenic C. difficile in the stools by PCR or enzyme-linked immunosorbent assay or immunochromatography or toxigenic culture) within 6 months with an interval ≤ 12 weeks since the end of treatment of the previous episode of resolved CDI with at least one of the following risk factors:

    • Age ≥70 years
    • Chronic renal failure (haemodialysis or GFR<60ml/min
    • History of severe or severe-complicated CDI (excluding current episode) according to ESCMID 2021 criteria
    • ≥3 CDI in the last 12 months (including current episode)
    • CDI associated with care defined as CDI occurring during hospitalisation (<3 months)
  • On current or planned vancomycin treatment per os

  • Patient able to give free, informed and written consent

  • Enrolled in compulsory national social security scheme

Exclusion Criteria:

  • Currently participating or has participated in a study with an investigational compound or device within 3 months prior to the first dose of the study intervention.
  • Severe C. difficile infection severe (defined by the presence of a white blood cell count >15×10⁹ cells/L or a body temperature >38.5°C or >50% increase in the patient's baseline creatinine related to CDI at the time of V1) and/or complicated (defined by any of the factors attributed to current Clostridioides difficile infection (CDI): hypotension, septic shock, elevated serum lactate, ileus, toxic megacolon, intestinal perforation or any fulminant course of the disease)
  • Refractory C. difficile infection defined as lack of response to well-conducted per os vancomycin or fidaxomicin treatment with ≥3 liquid stools per day after ≥5 days of treatment
  • Cirrhosis with Child C score
  • Hospitalization in continuing care unit or intensive care unit
  • Personal history of gastrointestinal resection other than appendectomy (gastrectomy, esophagectomy, colonic or small bowel resection, short small bowel syndrome).
  • Personal history of gastrointestinal resection resulting in chronic diarrhea (>3 loose stools per day)
  • Inflammatory bowel disease
  • Proven uncontrolled celiac disease
  • Current stoma (ileostomy or colostomy) or within the last 6 months, or any other intra-abdominal surgery within the 3 months prior to treatment
  • major surgery or trauma ≤ 4 weeks before the start of treatment or, if > 4 weeks ago, with an unresolved healing process that could affect the assessment or safety of the study treatment.
  • Antibiotic therapy in progress or planned during the study for an infection other than CDI
  • Surgery scheduled during the study requiring perioperative antibiotics.
  • -Women without contraception*, pregnant or breastfeeding women
  • History of hypersensitivity to EXL01 and/or to any of its excipients (D-mannitol, sucrose, maltodextrin, L-cysteine, L-cysteine hydrochloride, magnesium stearate and hydroxypropylmethylcellulose), and/or to soy or soy-containing products.
  • History of hypersensitivity to vancomycin as mentioned in local prescribing information.
  • Personal history of fecal microbiota transplantation < 6 months
  • Persons deprived of liberty by judicial or administrative decision
  • Adults under legal protection or unable to give consent
  • Swallowing disorders making oral treatment impossible
  • Participation in another interventional study within 3 months prior to inclusion. (Patients who have entered the follow-up phase of an interventional study may participate provided that more than 3 months have elapsed since the last intervention).
  • Expected life expectancy of less than 6 months
  • Presents a known psychiatric disorder that would interfere with adequate cooperation with study requirements.
  • Regular use of illicit or recreational drugs that may interfere with the administration of the medication or the interpretation of the data
  • History of chronic diarrhea (> 3 watery stools per day for > 4 weeks) not related to gastrointestinal infection.
  • Clinically significant medical or surgical condition not mentioned in the above criteria which, in the opinion of the investigator, could interfere with the administration of study drug, the interpretation of study safety or efficacy data, or compromise the safety or well-being of the subject.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Partie A (EXL01 en ouvert)

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period
Expérimental: Partie B (EXL01)

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase I : EXL01 during a 8 weeks open-label period

Following a at least 10-days vancomycin treatment :

Oral EXL01 including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase II: EXL01 during a 8 weeks double blind placebo-controlled period
Comparateur placebo: Partie B (Placebo)

Following a at least 10-days vancomycin treatment:

Oral placebo including:

  • 10 capsules per day in week 1 and 2
  • 4 capsules per day, in weeks 3 and 4
  • 1 capsule per day in weeks 5 to 8 Phase II : Placebo during a 8 weeks double blind placebo-controlled period

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of Treatment-Emergent Adverse Events
Délai: at Week 1, Week 2, Week 4, Week 8, Week 16

Phase I The primary endpoint is the occurrence of serious adverse events (CTCAE grade≥3) during treatment and follow-up and discontinuation of treatment due to adverse events attributed to treatment

at Week 1, Week 2, Week 4, Week 8, Week 16
Evaluation of the efficacy of EXL01 in preventing recurrence of C. difficile infection in patients at high risk of recurrence
Délai: at Week 8

Phase II The primary endpoint is the proportion of patients at W8 after the start of treatment who had a recurrence of toxigenic C. difficile defined by ≥3 liquid stools per day for more than 48 hours + detection of C. difficile toxin in stool (enzyme-linked immunosorbent assay or toxigenic culture +/- PCR) resulting in the initiation of CDI-specific treatment.

at Week 8

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Evaluation of the efficacy of EXL01 in preventing recurrence of C. difficile infection in patients at high risk of recurrence
Délai: at Week 8

Phase I Proportion of patients at W8 after the start of treatment who had a recurrence of toxigenic C. difficile defined by ≥3 liquid stools per day for more than 48 hours + detection of C. difficile toxin in stool (enzyme-linked immunosorbent assay or toxigenic culture +/- PCR) resulting in the initiation of specific treatment for CDI.

at Week 8
Evaluation of the safety and tolerability profile of oral EXL01
Délai: at Week 2, Week 4, Week 8, Week 16

Phase II Occurrence of adverse events (CTCAE grade≥3) during treatment and follow-up, and discontinuation of treatment due to adverse events

at Week 2, Week 4, Week 8, Week 16
Number of stools per day over the past 24 hours
Délai: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit using a stool calendar

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
Stool consistency, as assessed by the Bristol scale, over the past 24 hours
Délai: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Digestive symptoms are measured at each visit using the stool calendar

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
Abdominal discomfort assessed by a validated irritable bowel syndrome scale
Délai: at Week 8, Week 16

Phase I Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit (IBS-SSS modified, GCSI, GERDQ)

at Week 8, Week 16
Number of stools per day over the past 24 hours
Délai: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit using a stool calendar

at Week 0, Week 2, Week 4, Week 8, Week 16
Stool consistency, as assessed by the Bristol scale, over the past 24 hours
Délai: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Digestive symptoms are measured at each visit using the stool calendar

at Week 0, Week 2, Week 4, Week 8, Week 16
Abdominal discomfort assessed by a validated irritable bowel syndrome scale
Délai: at Week 8, Week 16

Phase II Assessment of digestive symptoms during treatment and follow-up Digestive symptoms are measured at each visit (IBS-SSS modified, GCSI, GERDQ)

at Week 8, Week 16
Assessment of patient quality of life during treatment and follow-up
Délai: At Week 8 and Week 16

Phases I and II Patient quality of life at W8 and M4 measured by a validated digestive disease quality of life questionnaire (GIQLI)

At Week 8 and Week 16
Assessment of recurrence of C. difficile infection
Délai: At Week 16

Phases I and II percentage of patients with recurrence of C. difficile infection at M4

At Week 16
Evaluation of the presence of EXL01 in the fecal microbiota
Délai: At Week 8

Phases I and II Level of F. prausnitzii (qPCR) in stool at W8 versus W0

At Week 8
Assessment of EXL01 persistence in the intestinal microbiota
Délai: At Week 0 and Week 16

Phases I and II Level of F. prausnitzii (qPCR) in stool at M4 versus W0

At Week 0 and Week 16
16S rRNA sequencing or shotgun
Délai: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Gut microbiota composition at each visit

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
16S rRNA sequencing or shotgun
Délai: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Gut microbiota composition at each visit

at Week 0, Week 2, Week 4, Week 8, Week 16
Assessment of the persistence of toxigenic C. difficile in the stool of patients in clinical remission during the study.
Délai: at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16

Phase I Percentage of patients at each visit with a positive stool PCR test for toxigenic C. difficile considered to be in clinical remission

at Week 0, Week 1, Week 2, Week 4, Week 8, Week 16
Assessment of the persistence of toxigenic C. difficile in the stool of patients in clinical remission during the study.
Délai: at Week 0, Week 2, Week 4, Week 8, Week 16

Phase II Percentage of patients at each visit with a positive stool PCR test for toxigenic C. difficile considered to be in clinical remission

at Week 0, Week 2, Week 4, Week 8, Week 16
Assessment of recurrences of C. difficile infection requiring hospitalization
Délai: At Week 8

phases I and II percentage of patients with recurrence of C. difficile infection requiring hospitalization at W8

At Week 8
Assessment of recurrences of C. difficile infection requiring hospitalization
Délai: at Week 16

phases I and II percentage of patients with recurrence of C. difficile infection requiring hospitalization at M4

at Week 16
Assessment of recurrences of C. difficile infection requiring surgery
Délai: at Week 8

phases I and II phases I and II percentage of patients with a recurrence of C. difficile infection requiring surgery at W8

at Week 8
Assessment of recurrences of C. difficile infection requiring surgery
Délai: at Week 16

phases I and II percentage of patients with recurrent C. difficile infection requiring surgery at M4

at Week 16

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Chercheur principal: Nicolas BENECH, MD, Hospices Civils de Lyon

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

7 mai 2024

Achèvement primaire (Estimé)

7 janvier 2028

Achèvement de l'étude (Estimé)

7 janvier 2028

Dates d'inscription aux études

Première soumission

21 février 2024

Première soumission répondant aux critères de contrôle qualité

5 mars 2024

Première publication (Réel)

12 mars 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

19 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 69HCL22_0980
  • 2023-506232-32-00 (Autre identifiant: EU CT Number)
  • 2023 (Subvention/contrat des NIH des États-Unis)

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .